SomaGenics strengthens its IP and technology position in small RNA analysis and biomarker discovery with new patent and publication

Santa Cruz, CA, September 2018 - SomaGenics announced today the issue of US Patent 10,041,107, a continuation of SomaGenics’ patent family entitled “Methods and Compositions for Detection of small RNAs.” The new patent broads protection for SomaGenics’ innovative, circularization-based approaches to accurately detect and quantify small RNAs, including key technologies incorporated in SomaGenics’ RealSeq® NGS sequencing kits for total RNA samples and for biofluids. 

Read More

SomaGenics selected to present at Military Health System Research Symposium 2018

Santa Cruz, CA, August 2018 - SomaGenics, Inc. has been selected to present its work in chronic wound healing at the Military Health System Research Symposium (MHSRS),  August 20-23rd in Kissimmee FL.  The Company will present a talk titled, “Skin Regeneration & Scar Mitigation - Acceleration of Wound Healing with PHD2- and miR-210-targeting Oligonucleotides.” 

Read More

SomaGenics launches its RealSeq®-biofluids kit and advances liquid biopsy development with new NIH funding for cf-miRNA NGS technology

Santa Cruz, CA, May 2018 - SomaGenics announced the launch of RealSeq®-biofluids, a next-generation sequencing (NGS) library construction kit sensitive enough to detect small RNAs from cell-free biofluids. Further enhancing its efforts in the liquid biopsy arena, SomaGenics has received a 3-year Phase II SBIR grant from the NIH for the development of RealSeq®-T, a technology enabling extraction-free, targeted NGS of small RNAs directly from biofluids.

Read More

SomaGenics Announces Upcoming Data Presentations of its Wound Healing Therapeutic Program

Santa Cruz, CA, April 2018 - SomaGenics, Inc. today announced two forthcoming presentations and a publication on preclinical results of its wound healing therapeutic program. SomaGenics’ NIH-funded project to accelerate wound healing in diabetic patients aims at restoring the normal wound-healing response, which is impaired in diabetics.

Read More

SomaGenics receives award or allowance of four patents covering its small RNA analysis and therapeutics

Santa Cruz, CA, December 2017 – SomaGenics Inc. expands its IP protection with three newly issued patents by the United States Patent and Trademark Office covering two of the Company’s core RNA detection technologies: targeted small RNA sequencing (RealSeq®-T) and quantitative PCR analysis of RNA fragments (ResQ®), as well as SomaGenics’ therapeutic sshRNA®s. A patent covering RealSeq®-T was also allowed by the European Patent Office.

Read More

SomaGenics awarded NIH funding to develop NGS Single-Cell analysis of small RNAs

Santa Cruz, CA, October 2017- SomaGenics announced the receipt of a Phase I SBIR grant from NIH to develop RealSeq®-SC (Single Cell), expected to be the first commercially available library preparation kit for profiling small RNAs (including microRNAs) from single cells using NGS methods. NIH's recent Single Cell Analysis Program highlights the need to accelerate development of approaches to analyze the heterogeneity of cell populations.

Read More

SomaGenics awarded NIH funding to develop novel cell-free-DNA liquid biopsy platform

Santa Cruz, CA, May 2017- SomaGenics announced the receipt of a Phase I SBIR grant from the National Human Genome Research Institute to support extension of its RealSeq® platform to the sequence analysis of highly fragmented cell-free DNA (cf-DNA).  The original version of this platform technology, RealSeq®-AC, allows construction of unbiased libraries for next-generation sequencing of small RNAs (such as microRNAs) and short fragments of large RNAs.  The new grant, entitled Advanced method for preparing cell-free (cf) DNA sequencing libraries, will support development of the DNA version, called RealSeq®-DC, and demonstration of its expected superiority over currently available methods for fragmented DNA-seq library preparation.

Read More

SomaGenics Presents RNAi Therapeutic Program

Santa Cruz, CA, May, 2017 – SomaGenics’ President and CEO, Brian Johnston, Ph.D., recently presented an invited seminar, “Treating chronic diabetic wounds: A small RNA approach,” to the Institute for RNA Medicine of Beth Israel Deaconess Medical Center, just renamed the Harvard Medical School Initiative on RNA Medicine (IRM).  SomaGenics’ novel synthetic short hairpin RNA (sshRNA®) platform has been used to develop therapeutic candidates for chronic diabetic wounds as well as treatments for hepatitis delta virus.  Dr. Johnson was invited to serve on the IRM Business Advisory Board.  “I am looking forward to the opportunity to work with the IRM’s scientists and stakeholders and hope to contribute to advancing RNA-based treatments across many therapeutic areas.”

Read More

SomaGenics presented research progress at the Symposium on Advanced Wound Care and Wound Healing Society

Santa Cruz, CA, April 2017 – SomaGenics presented recent progress in its wound healing therapeutic program at the joint meeting of the Symposium on Advanced Wound Care and the Wound Healing Society (SAWC/WHS) in San Diego.   Brian Johnston, Ph.D., CEO of SomaGenics discussed SomaGenics’ use of its sshRNA® (synthetic short hairpin RNA) platform to treat chronic wounds in a diabetic animal model in a talk entitled “Treating chronic diabetic wounds: A small RNA approach.”  

Read More

SomaGenics Granted New Patents for RNA Detection and RNA-based Therapeutics Technologies

SANTA CRUZ, Calif., November 2016 – SomaGenics, an RNA-focused biotechnology company, announced expansion of its intellectual property portfolio with issue of two new patents for its RNA analysis technologies (miR-ID® and RealSeq®) and European patent protection for its therapeutic short synthetic hairpin RNA (sshRNA) agents.

Read More

Rubicon Genomics Licenses Commercialization Rights from SomaGenics for Its RealSeq®-AC Technology for High-Throughput Sequencing of Small RNAs

Santa Cruz, Calif. July 28 2016 - SomaGenics Inc. today announced that it has signed a licensing agreement with Rubicon Genomics, Inc. for commercialization of SomaGenics’ RealSeq®-AC library preparation technology for sequencing small RNAs, including micro-RNAs and small fragments of large RNAs.  Further terms of the agreement were not disclosed.

Read More